- Home
- VNDA vs NUW Comparison
VNDA vs NUW Comparison
Compare VNDA & NUW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VNDA
- NUW
- Stock Information
- Founded
- VNDA 2002
- NUW 2008
- Country
- VNDA United States
- NUW United States
- Employees
- VNDA N/A
- NUW N/A
- Industry
- VNDA Biotechnology: Pharmaceutical Preparations
- NUW Investment Managers
- Sector
- VNDA Health Care
- NUW Finance
- Exchange
- VNDA Nasdaq
- NUW Nasdaq
- Market Cap
- VNDA 249.4M
- NUW 246.8M
- IPO Year
- VNDA 2006
- NUW N/A
- Fundamental
- Price
- VNDA $4.75
- NUW $13.64
- Analyst Decision
- VNDA Strong Buy
- NUW
- Analyst Count
- VNDA 2
- NUW 0
- Target Price
- VNDA $16.50
- NUW N/A
- AVG Volume (30 Days)
- VNDA 551.9K
- NUW 45.3K
- Earning Date
- VNDA 07-31-2025
- NUW 01-01-0001
- Dividend Yield
- VNDA N/A
- NUW 3.66%
- EPS Growth
- VNDA N/A
- NUW N/A
- EPS
- VNDA N/A
- NUW N/A
- Revenue
- VNDA $203,467,000.00
- NUW N/A
- Revenue This Year
- VNDA $16.86
- NUW N/A
- Revenue Next Year
- VNDA $39.78
- NUW N/A
- P/E Ratio
- VNDA N/A
- NUW N/A
- Revenue Growth
- VNDA 11.78
- NUW N/A
- 52 Week Low
- VNDA $3.81
- NUW $12.45
- 52 Week High
- VNDA $5.55
- NUW $14.44
- Technical
- Relative Strength Index (RSI)
- VNDA 60.39
- NUW 48.40
- Support Level
- VNDA $4.47
- NUW $13.50
- Resistance Level
- VNDA $4.88
- NUW $13.85
- Average True Range (ATR)
- VNDA 0.16
- NUW 0.10
- MACD
- VNDA 0.05
- NUW -0.02
- Stochastic Oscillator
- VNDA 82.43
- NUW 31.82
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.
About NUW Nuveen AMT-Free Municipal Value Fund
Nuveen AMT-Free Municipal Value Fund is a diversified closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax by investing in a portfolio of municipal obligations. The fund predominantly invests in long-term municipal bonds, corporate bonds, short-term municipal bonds, and other assets.